The Future of Peritoneal Dialysis in a Moving Landscape of Bacterial Resistance

Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013; 12(5): 371–87.

Domargk G. Nobel lecture. Stockholm: Nobel prize.org; 1939; [Online.] Available from: http://nobelprize.org/nobel_prizes/medicine/laureates/1939/domagk-lecture.html.

Frank H.A. , Seligman A.M. , Fine J. Further experiences with peritoneal irrigation for acute renal failure including a description of modifications in method. Ann Surg 1948; 128(3): 561–608.

Fine J. , Frank H.A. , Seligman A.M. The treatment of acute renal failure by peritoneal irrigation. Ann Surg 1946; 124: 857–78.

Toleman M.A. , Walsh T.R. Combinatorial events of insertion sequences and ICE in gram-negative bacteria. FEMS Microbiol Rev 2011; 35(5): 912–35.

Mitsuhashi S. , Harada K. , Hashimoto H. , Egawa R. On the drug-resistance of enteric bacteria. 4. Drug-resistance of Shigella prevalent in Japan. Jpn J Exp Med 1961; 31: 47–52.

Hamad B. The antibiotics market. Nat Rev Drug Discov 2010; 9(9): 675–6.

Szeto C.C. Peritonitis rates of the past thirty years: from improvement to stagnation. Perit Dial Int 2014; 34(2): 151–3.

van Esch S. , Krediet R.T. , Struijk D.G. 32 years’ experience of peritoneal dialysis-related peritonitis in a university hospital. Perit Dial Int 2014; 34(2): 162–70.

Mushahar L. , Mei L.W. , Yusuf W.S. , Sivathasan S. , Kamaruddin N. , Idzham N.J. Exit-site dressing and infection in peritoneal dialysis: a randomized controlled pilot trial. Perit Dial Int 2016; 36(2): 135–9.

Szeto C.C. , Wong T.Y. , Chow K.M. , Leung C.B. , Li P.K. Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant 2003; 18(5): 977–82.

Li P.K. , Szeto C.C. , Piraino B. , de Arteaga J. , Fan S. , Figueiredo A.E. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36(5): 481–508.

Stinghen A.E. , Barretti P. , Pecoits-Filho R. Factors contributing to the differences in peritonitis rates between centers and regions. Perit Dial Int 2007; 27(Suppl 2): S281–5.

Szeto C.C. Peritoneal dialysis-related infection in the older population. Perit Dial Int 2015; 35(6): 659–62.

Tang W. , Grace B. , McDonald S.P. , Hawley C.M. , Badve S.V. , Boudville N.C. Socio-economic status and peritonitis in Australian non-indigenous peritoneal dialysis patients. Perit Dial Int 2015; 35(4): 450–9.

Akoh J.A. Peritoneal dialysis associated infections: an update on diagnosis and management. World J Nephrol 2012; 1(4): 106–22.

Szeto C.C. , Leung C.B. , Chow K.M. , Kwan B.C. , Law M.C. , Wang A.Y. Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in South-East Asia. Clin Microbiol Infect 2005; 11(10): 837–9.

Prasad N. , Gupta A. , Sharma R.K. , Prasad K.N. , Gulati S. , Sharma A.P. Outcome of gram-positive and gram-negative peritonitis in patients on continuous ambulatory peritoneal dialysis: a single-center experience. Perit Dial Int 2003; 23(Suppl 2): S144–7.

Gladziwa U. An unusual case of CAPD-related peritonitis associated with Candida albicans. Perit Dial Int 2015; 35(7): 765.

Li P.K. , Szeto C.C. , Piraino B. , Bernardini J. , Figueiredo A.E. , Gupta A. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30(4): 393–423.

Szeto C.C. , Chow K.M. Gram-negative peritonitis—the Achilles heel of peritoneal dialysis? Perit Dial Int 2007; 27(Suppl 2): S267–71.

Johnson J.R. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991; 4(1): 80–128.

Georgiades K. , Raoult D. Genomes of the most dangerous epidemic bacteria have a virulence repertoire characterized by fewer genes but more toxin-antitoxin modules. PLOS One 2011; 6(3): e17962.

Johnson J.R. , Kuskowski M.A. , Owens K. , Gajewski A. , Winokur P.L. Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. J Infect Dis 2003; 188(5): 759–68.

Perez Fontan M. , Rodriguez-Carmona A. , Garcia-Naveiro R. , Rosales M. , Villaverde P. , Valdes F. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25(3): 274–84.

Barretti P. , Montelli A.C. , Batalha J.E. , Caramori J.C. , Cunha Mde L. The role of virulence factors in the outcome of staphylococcal peritonitis in CAPD patients. BMC Infect Dis 2009; 9: 212.

Projan S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6(5): 427–30.

Rolinson G.N. Forty years of beta-lactam research. J Antimicrob Chemother 1998; 41(6): 589–603.

Johnson A.P. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother 2011; 66(Suppl 4): iv43–8.

Johnson A.P. , Aucken H.M. , Cavendish S. , Ganner M. , Wale M.C. , Warner M. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001; 48(1): 143–4.

Livermore D.M. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39(4): 283–94.

Public Health England. Annual Epidemiological Commentary: Mandatory MRSA, MSSA and E coli bacteraemia and C. difficile infection data, 2013/14 (cited 25/8/2016). Public Health England; 2014. [Online.] Available from https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary.

European Centre for Disease Prevention and Control. Annual report of antimicrobial resistance and healthcare-associated infections: annual epidemiological report 2014. (cited 25/8/2016). [Online.] Available from: http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-annual-epidemiological-report.pdf

Center for Disease Dynamics Economics and Policy. Resistance map: United States. Washington; 2015 [updated 2015; cited 2016 25/8/2016]. [Online.] Available from: http://resistancemap.cddep.org/resmap/c/us/United%20States.

Klein E.Y. , Sun L. , Smith D.L. , Laxminarayan R. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study. Am J Epidemiol 2013; 177(7): 666–74.

Gould I.M. VRSA-doomsday superbug or damp squib? Lancet Infect Dis 2010; 10(12): 816–8.

Center for Disease Control and Prevention. Investigation and control of vancomycin-resistant Staphylococcus aureus (VRSA): 2015 update. Atlanta, GA; 2015 [updated 2015 4/2015; cited 2016 25/8/2016]. [Online.] Available from: http://www.cdc.gov/hai/pdfs/VRSA-Investigation-Guide-05_12_2015.pdf.

Becker K. , Heilmann C. , Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev 2014; 27(4): 870–926.

Blair J.M. , Richmond G.E. , Piddock L.J. Multidrug efflux pumps in gram-negative bacteria and their role in antibiotic resistance. Future Microbiol 2014; 9(10): 1165–77.

Crossman L.C. , Gould V.C. , Dow J.M. , Vernikos G.S. , Okazaki A. , Sebaihia M. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol 2008; 9(4): R74.

Fisher J.F. , Meroueh S.O. , Mobashery S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev 2005; 105(2): 395–424.

Lahey Clinic. Beta-lactamase classification. 2016 [updated 2016; cited 2016 25/8/2016]. [Online.] Available from: http://www.lahey.org/studies/.

Bush K. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci 2013; 1277: 84–90.

Evans B.A. , Hamouda A. , Amyes S.G. The rise of carbapenem-resistant Acinetobacter baumannii. Current Pharmaceut Des 2013; 19(2): 223–38.

European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Stockholm: ECDC; 2013. [Online.] Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf.

Livermore D.M. , Hawkey P.M. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56(3): 451–4.

Nicolas-Chanoine M.H. , Bertrand X. , Madec J.Y. Escherichia coli ST131, an intriguing clonal group. Clinic Microbiol Rev 2014; 27(3): 543–74.

Hawser S.P. , Bouchillon S.K. , Hoban D.J. , Badal R.E. , Hsueh P.R. , Paterson D.L. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009; 53(8): 3280–4.

Karim A. , Poirel L. , Nagarajan S. , Nordmann P. Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 2001; 201(2): 237–41.

Tangden T. , Cars O. , Melhus A. , Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54(9): 3564–8.

Wickramasinghe N.H. , Xu L. , Eustace A. , Shabir S. , Saluja T. , Hawkey P.M. High community faecal carriage rates of CTX-M ESBL-producing Escherichia coli in a specific population group in Birmingham, UK. J Antimicrob Chemother 2012; 67(5): 1108–13.

Lartigue M.F. , Poirel L. , Aubert D. , Nordmann P. In vitro analysis of ISEcp1B-mediated mobilization of naturally occurring beta-lactamase gene blaCTX-M of Kluyvera ascorbata. Antimicrob Agents Chemother 2006; 50(4): 1282–6.

Nordmann P. , Naas T. , Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17(10): 1791–8.

Queenan A.M. , Bush K. Carbapenemases: the versatile beta-lactamases. Clinic Microbiol Rev 2007; 20(3): 440–58.

Yigit H. , Queenan A.M. , Anderson G.J. , Domenech-Sanchez A. , Biddle J.W. , Steward C.D. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumonia. Antimicrob Agents Chemother 2001; 45(4): 1151–61.

Schwaber M.J. , Lev B. , Israeli A. , Solter E. , Smollan G. , Rubinovitch B. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52(7): 848–55.

Yong D. , Toleman M.A. , Giske C.G. , Cho H.S. , Sundman K. , Lee K. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53(12): 5046–54.

Kumarasamy K.K. , Toleman M.A. , Walsh T.R. , Bagaria J. , Butt F. , Balakrishnan R. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10(9): 597–602.

Toleman M.A. , Bugert J.J. , Nizam S.A. Extensively drug-resistant New Delhi metallo-β-lactamase–encoding bacteria in the environment, Dhaka, Bangladesh, 2012. Emerg Infect Dis 2015; 21(6): 1027–30.

Berrazeg M. , Diene S. , Medjahed L. , Parola P. , Drissi M. , Raoult D. New Delhi Metallo-beta-lactamase around the world: an eReview using Google Maps. Euro Surveill 2014; 19(20).

Toleman M.A. , Spencer J. , Jones L. , Walsh T.R. BlaNDM-1 is a chimera, likely constructed in Acinetobacter baumanii. Antimicrob Agents Chemother 56(5): 2773–6.

Nordmann P. , Poirel L. , Toleman M.A. , Walsh T.R. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by gram-negative bacteria? J Antimicrob Chemother 2011; 66(4): 689–92.

Walsh T.R. , Toleman M.A. The new medical challenge: why NDM-1? Why Indian? Expert Rev Anti Infect Ther 2011; 9(2): 137–41.

Walsh T.R. , Weeks J. , Livermore D.M. , Toleman M.A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11(5): 355–62.

Perry J.D. , Naqvi S.H. , Mirza I.A. , Alizai S.A. , Hussain A. , Ghirardi S. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother 2011; 66(10): 2288–94.

Wang X. , Liu W. , Zou D. , Li X. , Wei X. , Shang W. High rate of New Delhi metallo-beta-lactamase 1-producing bacterial infection in China. Clinical Infect Dis 2013; 56(1): 161–2.

Ghafur A.K. An obituary—on the death of antibiotics. J Assoc Physicians India 2010; 58: 143–4.

Liu Y.Y. , Wang Y. , Walsh T.R. , Yi L.X. , Zhang R. , Spencer J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16(2): 161–8.